Stock BDSX BIODESIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Biodesix, Inc.

Equities

BDSX

US09075X1081

Delayed Nasdaq
Other stock markets
 03:49:13 2024-05-21 pm EDT 		5-day change 1st Jan Change
1.57 USD 0.00% Intraday chart for Biodesix, Inc. +4.35% -15.22%
May. 13 TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target MT
May. 08 Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024

Evolution of the average Target Price on Biodesix, Inc.

Price target over the last 5 years

History of analyst recommendation changes

15e69ab4055039d4524ea3fe47.2R3PHjRzw5-C7_xsZmuoUkfha0kUMDVIaCUV_YZ0aJo.uHfiQV9DkfjQoLEUAQTBJASwLXAlAX4pBkRay844A8rhaLwmBCeb5daHuQ~237776ecf42171e6cbabcad4ff0a5a03

Analyst Recommendations on Biodesix, Inc.

TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target MT
Morgan Stanley Lowers Biodesix's Price Target to $5 From $7, Maintains Equalweight Rating MT
Biodesix Shares Rise After Cowen Starts Coverage With Outperform Rating MT
Cowen Starts Biodesix at Outperform MT
Canaccord Genuity Adjusts Price Target on Biodesix to $10 From $18, Reiterates Buy Rating MT
Morgan Stanley Adjusts Biodesix Price Target to $7 From $11, Maintains Equal Weight Rating MT
Canaccord Genuity Adjusts Price Target on Biodesix to $18 From $22, Reiterates Buy Rating MT
Morgan Stanley Downgrades Biodesix to Equalweight from Overweight, Adjusts Price Target to $11 from $21 MT
BIODESIX : Canaccord Genuity Adjusts Price Target on Biodesix to $27 From $31, Reiterates Buy Rating MT
BIODESIX : Morgan Stanley Adjusts Price Target on Biodesix to $23 From $25, Keeps Overweight Rating MT
BIODESIX : Morgan Stanley Adjusts Price Target on Biodesix to $25 From $20, Maintains Overweight Rating MT
BIODESIX : Canaccord Genuity Adjusts Biodesix' Price Target to $31 from $27, Keeps Buy Rating MT
BIODESIX : William Blair Initiates Coverage on Biodesix With Outperform Rating MT
BIODESIX : BTIG Research Initiates Coverage on Biodesix With Buy Rating, $22 Price Target MT
BIODESIX : Morgan Stanley Initiates Coverage on Biodesix With Overweight Rating, $20 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.57 USD
Average target price
3.25 USD
Spread / Average Target
+107.01%
High Price Target
3.5 USD
Spread / Highest target
+122.93%
Low Price Target
3 USD
Spread / Lowest Target
+91.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Biodesix, Inc.

TD Cowen
Morgan Stanley
Cowen
Canaccord Genuity

Ratings for Biodesix, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BDSX Stock
  4. Consensus Biodesix, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW